Under the award, Exvastat will collaborate with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of the drug and test it in critically ill COVID-19 patients.
“The coronavirus pandemic has focussed attention on ARDS as a very serious condition with a high mortality rate and for which there are currently no approved therapies, even though it causes more fatalities every year than breast or prostate cancer,” said David Cavalla, Chief Executive Officer of Exvastat. “We are using a repurposing strategy backed by strong intellectual property and good preclinical as well as human validation of the effect of the drug to reduce pulmonary oedema; we now intend to reformulate and fast-track clinical development for this serious condition.”
The trial will investigate the potential benefit to COVID-19 patients who lack any approved therapeutic options and enter intensive care, the critical juncture of maximum stress on healthcare resources. The trial is expected to enroll 110 COVID-19 patients following a 4- to 6-month reformulation programme. Unlike antiviral approaches, imatinib operates through the inhibition of the host response, reducing the pulmonary oedema that is correlated with mortality in all forms of ARDS, and is therefore anticipated to be a robust mechanism against viral mutations. Imatinib is a well-described drug with a proven safety history, that has shown significant promise as a potential treatment for ARDS based on preclinical studies carried out in European and US institutions, as well as multiple clinical case reports of benefit in closely related conditions.
“We would like to congratulate Exvastat and its collaborators on their receipt of this prestigious award which recognises the importance of developing novel treatments for ARDS. We are proud to continue to support the team in their development of this important initiative,” said Dr Robert Tansley, Life Sciences Partner at Cambridge Innovation Capital and Chairman at Exvastat.
About Exvastat Ltd
Exvastat Ltd is a single asset biopharmaceutical company established in 2016 with investment from Cambridge Innovation Capital (CIC). The founders, Drs. David Cavalla and Andrew McElroy, bring extensive experience in drug repurposing and a proven track record of success in pharmaceutical product development. The company is working to identify and advance imatinib for the treatment of serious and life-threatening conditions in patient populations with significant areas of unmet need, including ARDS.
For more information, please visit the Exvastat website at http://www.exvastat.com/.